(Reuters) – Chinese drug developer and producer Jiangsu Hengrui Pharmaceuticals is seeking to raise up to HK$9.89 billion ($1.27 billion) in a Hong Kong listing, according to a regulatory filing made on Thursday.
The offer price will be between HK$41.45 and HK$44.05 per share, according to a prospectus filed by the company to the Hong Kong Stock Exchange.
The China-based company plans to offer 224.5 million H shares, which include 12.3 million shares allocated for Hong Kong retailers.
Dealings in shares on the Hong Kong Stock Exchange are expected to commence on May 23, the filing said.
($1 = 7.8042 Hong Kong dollars) (This story has been corrected to say ‘listing,’ not ‘IPO,’ in the headline and in paragraph 1)
(Reporting by Roshan Thomas in Bengaluru; Editing by Alan Barona)
